Pharma Stocks Rise as Trump's Tariff Decision May Benefit the Industry
Written by Emily J. Thompson, Senior Investment Analyst
Source: MarketWatch
Pharmaceutical Stocks Reaction: Pharmaceutical stocks experienced gains as traders reacted positively to President Trump's new tariff plan for drugmakers.
Tariff Announcement Details: Trump announced a 100% tariff on branded or patented pharmaceutical products unless the manufacturer is establishing or has plans for a U.S. plant.
Analyst Views on PPH
Wall Street analysts forecast PPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 105.800
Low
Averages
High
Current: 105.800
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
